CY1123425T1 - Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων - Google Patents
Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτωνInfo
- Publication number
- CY1123425T1 CY1123425T1 CY20201100509T CY201100509T CY1123425T1 CY 1123425 T1 CY1123425 T1 CY 1123425T1 CY 20201100509 T CY20201100509 T CY 20201100509T CY 201100509 T CY201100509 T CY 201100509T CY 1123425 T1 CY1123425 T1 CY 1123425T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ton
- specifically
- functional parts
- rsv antibodies
- rsv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927819P | 2014-01-15 | 2014-01-15 | |
| PCT/US2015/011391 WO2015108967A2 (en) | 2014-01-15 | 2015-01-14 | Rsv-specific antibodies and functional parts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123425T1 true CY1123425T1 (el) | 2021-12-31 |
Family
ID=53543612
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100509T CY1123425T1 (el) | 2014-01-15 | 2020-06-05 | Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων |
| CY2023011C CY2023011I2 (el) | 2014-01-15 | 2023-04-25 | Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2023011C CY2023011I2 (el) | 2014-01-15 | 2023-04-25 | Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US20160340414A1 (https=) |
| EP (3) | EP3741390A1 (https=) |
| JP (4) | JP6836398B2 (https=) |
| KR (1) | KR102188437B1 (https=) |
| CN (2) | CN116355080A (https=) |
| AU (4) | AU2015206570A1 (https=) |
| CA (1) | CA2933200C (https=) |
| CY (2) | CY1123425T1 (https=) |
| DK (1) | DK3094353T3 (https=) |
| ES (1) | ES2795727T3 (https=) |
| FI (1) | FIC20230016I1 (https=) |
| FR (1) | FR23C1016I1 (https=) |
| HR (1) | HRP20200607T1 (https=) |
| HU (2) | HUE048855T2 (https=) |
| LT (2) | LT3094353T (https=) |
| LU (1) | LUC00305I2 (https=) |
| MX (1) | MX374517B (https=) |
| NL (1) | NL301228I2 (https=) |
| NO (1) | NO2023016I1 (https=) |
| PL (1) | PL3094353T3 (https=) |
| PT (1) | PT3094353T (https=) |
| RS (1) | RS60387B1 (https=) |
| SI (1) | SI3094353T1 (https=) |
| SM (1) | SMT202000282T1 (https=) |
| TW (1) | TWI705974B (https=) |
| WO (1) | WO2015108967A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| ES2795727T3 (es) | 2014-01-15 | 2020-11-24 | Medimmune Llc | Anticuerpos específicos del vrs y partes funcionales de los mismos |
| US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| KR20200140799A (ko) * | 2018-01-31 | 2020-12-16 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물 |
| CN111606993B (zh) * | 2019-02-26 | 2022-06-28 | 中国科学院上海生命科学研究院 | 抗呼吸道合胞病毒的全人广谱中和抗体4f1及其应用 |
| US12024553B2 (en) | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
| CA3229901A1 (en) | 2021-09-13 | 2023-03-16 | Medimmune Limited | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
| CN119264248A (zh) * | 2022-07-22 | 2025-01-07 | 北京智仁美博生物科技有限公司 | 抗呼吸道合胞病毒中和性抗体及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO2006050166A2 (en) * | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
| AU2005335714B2 (en) * | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| MX2009003306A (es) | 2006-10-02 | 2009-04-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y sus usos. |
| JP2010534057A (ja) * | 2007-03-06 | 2010-11-04 | シムフォゲン・アクティーゼルスカブ | 呼吸器合胞体ウイルス感染症を治療するための組換え抗体 |
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| US20110008329A1 (en) * | 2007-06-26 | 2011-01-13 | Medlmmune, Llc | Methods of Treating RSV Infections And Related Conditions |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| TWI478937B (zh) | 2008-01-15 | 2015-04-01 | Abbvie Inc | 改良之哺乳動物表現載體及其用途 |
| US9273118B2 (en) * | 2009-07-15 | 2016-03-01 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| JP5762408B2 (ja) * | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法 |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| EP2486053B1 (en) * | 2009-10-06 | 2017-01-18 | Medimmune Limited | Rsv-specific binding molecule |
| US20120263715A1 (en) | 2009-10-28 | 2012-10-18 | Medimmune, Llc | Topical Methods Of Treating RSV Infections And Related Conditions |
| BR112012031638B1 (pt) * | 2010-07-09 | 2021-01-12 | Janssen Vaccines & Prevention B.V. | anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado |
| CA2867444C (en) * | 2012-03-16 | 2021-04-13 | University Health Network | Compositions containing soluble toso protein and uses thereof |
| US20150158942A1 (en) * | 2012-05-22 | 2015-06-11 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 antibodies for treatment of scleroderma |
| CA2900110A1 (en) | 2013-02-01 | 2014-08-07 | Medimmune, Llc | Respiratory syncytial virus f protein epitopes |
| ES2795727T3 (es) * | 2014-01-15 | 2020-11-24 | Medimmune Llc | Anticuerpos específicos del vrs y partes funcionales de los mismos |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| BR112019018022A2 (pt) | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
-
2015
- 2015-01-14 ES ES15737068T patent/ES2795727T3/es active Active
- 2015-01-14 AU AU2015206570A patent/AU2015206570A1/en not_active Abandoned
- 2015-01-14 KR KR1020167020393A patent/KR102188437B1/ko active Active
- 2015-01-14 PL PL15737068T patent/PL3094353T3/pl unknown
- 2015-01-14 PT PT157370685T patent/PT3094353T/pt unknown
- 2015-01-14 EP EP20161884.0A patent/EP3741390A1/en not_active Withdrawn
- 2015-01-14 HU HUE15737068A patent/HUE048855T2/hu unknown
- 2015-01-14 CA CA2933200A patent/CA2933200C/en active Active
- 2015-01-14 EP EP15737068.5A patent/EP3094353B1/en active Active
- 2015-01-14 US US15/111,610 patent/US20160340414A1/en not_active Abandoned
- 2015-01-14 EP EP23215838.6A patent/EP4353316A3/en active Pending
- 2015-01-14 SI SI201531183T patent/SI3094353T1/sl unknown
- 2015-01-14 HR HRP20200607TT patent/HRP20200607T1/hr unknown
- 2015-01-14 CN CN202211184987.8A patent/CN116355080A/zh active Pending
- 2015-01-14 DK DK15737068.5T patent/DK3094353T3/da active
- 2015-01-14 RS RS20200640A patent/RS60387B1/sr unknown
- 2015-01-14 SM SM20200282T patent/SMT202000282T1/it unknown
- 2015-01-14 JP JP2016541720A patent/JP6836398B2/ja active Active
- 2015-01-14 LT LTEP15737068.5T patent/LT3094353T/lt unknown
- 2015-01-14 CN CN201580003410.4A patent/CN105916520A/zh active Pending
- 2015-01-14 MX MX2016008639A patent/MX374517B/es active IP Right Grant
- 2015-01-14 WO PCT/US2015/011391 patent/WO2015108967A2/en not_active Ceased
- 2015-01-15 TW TW104101373A patent/TWI705974B/zh active
-
2018
- 2018-06-08 US US16/003,455 patent/US10689437B2/en active Active
-
2020
- 2020-02-10 JP JP2020020602A patent/JP2020103293A/ja active Pending
- 2020-05-01 US US16/864,454 patent/US11186628B2/en active Active
- 2020-06-05 CY CY20201100509T patent/CY1123425T1/el unknown
- 2020-06-10 AU AU2020203831A patent/AU2020203831A1/en not_active Abandoned
-
2021
- 2021-06-25 AU AU2021204339A patent/AU2021204339B2/en active Active
- 2021-10-22 US US17/451,955 patent/US11661449B2/en active Active
-
2023
- 2023-01-27 JP JP2023010903A patent/JP2023052693A/ja active Pending
- 2023-04-18 US US18/302,400 patent/US12173050B2/en active Active
- 2023-04-25 NO NO2023016C patent/NO2023016I1/no unknown
- 2023-04-25 FR FR23C1016C patent/FR23C1016I1/fr active Active
- 2023-04-25 CY CY2023011C patent/CY2023011I2/el unknown
- 2023-04-26 NL NL301228C patent/NL301228I2/nl unknown
- 2023-04-26 FI FIC20230016C patent/FIC20230016I1/fi unknown
- 2023-04-27 LU LU00305C patent/LUC00305I2/fr unknown
- 2023-04-28 LT LTPA2023514C patent/LTC3094353I2/lt unknown
- 2023-05-02 HU HUS2300019C patent/HUS2300019I1/hu unknown
-
2024
- 2024-11-11 US US18/943,007 patent/US20250179153A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003702A patent/JP2025063143A/ja active Pending
- 2025-02-14 AU AU2025201056A patent/AU2025201056A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123425T1 (el) | Ειδικα για ton rsv αντισωματα και λειτουργικα τμηματα αυτων | |
| CY1125267T1 (el) | Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn | |
| CO2019001980A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos | |
| EA202092435A2 (ru) | Моноклональные антитела против bcma | |
| EA201790173A1 (ru) | Антитела, связывающие axl | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| HK1257056A1 (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
| MX375524B (es) | Anticuerpos anti-axl. | |
| EA201692425A1 (ru) | Модифицированные биополимеры и способы их получения и использования | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| MX2016016883A (es) | Anticuerpo anti-axl. | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| DK3265123T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| EP3191128A4 (en) | Uses of anti-her3 antibodies for treating cancer | |
| CY1120569T1 (el) | Πρωτεϊνες ειδικες για baff και b7rp1 και χρησεις αυτων | |
| CO2017010143A2 (es) | Procesos para preparar fluorocetólidos | |
| EA201591709A1 (ru) | 5-бром-индирубины | |
| EA201990505A1 (ru) | Анти-tigit антитела, анти-pvrig антитела и их комбинации |